Long-lasting flea and tick protection that makes a difference
Compliance | Testimonials | Innovation | Safety | FAQs | Offers | Guarantee
Discover the ONLY options for extended-duration canine and feline flea and tick prevention with BRAVECTO®
BRAVECTO provides a variety of options for long-lasting flea and tick protection. Both BRAVECTO® Chews and BRAVECTO® Topical Solution offer 12-week* extended-duration protection while BRAVECTO® PLUS allows cats to enjoy 2 months of protection against fleas, ticks, and heartworms. When you choose BRAVECTO, you can help pet owners find what works best for them to ensure year-round compliance.
The 4 key differences of BRAVECTO
Offers an easy transition to life-long extended-duration protection
Extended-duration protection, for adult dogs and puppies 6 months of age and older, available as a chew or topical dose
With options for 2-month† flea, tick, and heartworm protection and 12-week flea and tick topical protection1-3
BRAVECTO delivers fast-acting, effective protection, killing fleas and ticks within hours of administration1,4-8
Enhanced pet owner compliance
Compliance among pet owners increased with Bravecto, compared with monthly products.9
Pet owners purchase more months of coverage per year with BRAVECTO Chews vs monthly products9
Hear from veterinarians on how BRAVECTO has transformed flea and tick management
See the difference BRAVECTO makes for veterinarians and pet parents.
“As a busy pet parent myself, I know it can be hard to remember to give prevention every month. That’s why I love the convenience of BRAVECTO, as it lasts nearly 3X* longer than one dose of monthly chews.”
Dr. Molly Brinkmann
Veterinarian and Medical Director
The innovative difference in flea and tick protection brought to you by Merck Animal Health
Discover what makes fluralaner different
BRAVECTO (fluralaner) is an isoxazoline, a novel and specific blocker of insect ligand-gated chloride channels.1,4,7,10
BRAVECTO is the only isoxazoline that lasts 12 weeks.1,4,5* This decreases potential gaps in protection and provides greater compliance in tick and flea control.9
BRAVECTO is proven safe
PROVEN SAFETY
- No known contraindications for BRAVECTO Chews for Dogs and BRAVECTO Topical Solution for Dogs and Cats.1,4,5
- No problems reported in field trials in dogs and cats that received BRAVECTO concurrently with other commonly used medication.1,4,5
- BRAVECTO has not been shown to be effective for 12-week duration in puppies or kittens less than 6 months of age.4
- In field studies and safety studies, no dogs or cats experienced serious adverse events.1,2,4,5,11
- In margin of safety study, kittens and puppies were dosed at three 8-week intervals.
DOGS
BRAVECTO has been evaluated for use in breeding, pregnant, and lactating female dogs.4,5 BRAVECTO is safe to use and efficacious in adult dogs and puppies over 6 months of age and weighing 4.4 lbs or greater.5,6 It has been tested and found safe in puppies at least 8 to 9 weeks of age at 5x the clinical dose.4,5,12 No adverse effects with BRAVECTO Chews for Dogs in MDR-1 gene-deficient collies at 3x the recommended dose.13
CATS
BRAVECTO is safe to use and efficacious in adult cats and kittens over 6 months of age and weighing 2.6 lbs or greater. It has been tested and found safe in kittens at least 11 to 13 weeks of age at 5x the clinical dose.1
For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318.
Ask about the extended-duration difference
Speak with a Merck Animal Health representative for more information about BRAVECTO flea and tick protection for your hospital.
We’re here to answer any questions and help you start prescribing BRAVECTO for the dogs and cats in your care.
Frequently Asked Questions about BRAVECTO
BRAVECTO provides veterinarians nationwide with long-lasting flea and tick protection for dogs, cats, kittens, and puppies to promote longer, healthier lives. Twelve-week* extended-duration protection is available from both BRAVECTO Chews and BRAVECTO Topical Solution. Cats enjoy 2 months of protection against fleas, ticks, and heartworms with BRAVECTO PLUS. Thanks to BRAVECTO, you can help pet owners find what works best for them to ensure year-round compliance.
Compared with monthly products, products with a long-lasting duration decrease the chances of pet owners missing a dose, helping to enhance compliance and ensure protection.1,4,5,9
All BRAVECTO products kill adult Ctenocephalides felis (cat flea), prevent flea infestations, and kill multiple species of ticks. In dogs, these ticks include Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Rhipicephalus sanguineus (brown dog tick), and Amblyomma americanum (lone star tick). BRAVECTO Chews for Dogs and BRAVECTO 1-MONTH Chews also kills Haemaphysalis longicornis (Asian longhorned tick). In cats, these ticks include Ixodes scapularis (black-legged tick), Haemaphysalis longicornis (Asian longhorned tick), and Dermacentor variabilis (American dog tick).
All BRAVECTO products contain fluralaner, a trusted flea and tick preventive. Fluralaner is a member of the isoxazoline class. Isoxazoline is a novel and specific blocker of insect ligand-gated chloride channels.1,4,5,10
BRAVECTO products have been proven safe. There are no known contraindications for BRAVECTO Chews for Dogs, or BRAVECTO Topical Solution for Dogs and Cats.1,4,5 No problems have been reported in field trials in dogs and cats that received BRAVECTO concurrently with other commonly used medication.1,4,5 In field studies and safety studies, no dogs or cats experienced serious adverse events.1,2,4,5,11 In margin of safety study, kittens and puppies were dosed at three 8-week intervals. BRAVECTO has not been shown to be effective for 12-week duration in puppies or kittens less than 6 months of age.4
Offer pet owner savings
One dose of BRAVECTO flea and tick treatment lasts 12 weeks* compared with monthly products. That already makes it a cost-effective option for pet owners compared with monthly products. But now, you can help pet owners save even more on flea and tick control with BRAVECTO.
The satisfaction difference
We want to make sure your clients receive the results they expect. That’s why we’ve created the BRAVECTO Brand Promise—our way to show that we stand behind each of these innovative products. We are so confident in our BRAVECTO products that if your clients are dissatisfied, we’ll refund the purchase price and provide additional reimbursements. Contact our team of flea and tick control experts to see if your clients qualify for our BRAVECTO Brand Promise. Our team will work with you to ensure that your clients are satisfied.
For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318.
This site is intended for veterinary professionals. Visit our website for pet parents.
*BRAVECTO kills fleas and prevents flea infestations. BRAVECTO (fluralaner) Chews for Dogs kills ticks (black-legged tick, American dog tick, brown dog tick, and Asian longhorned tick) for 12 weeks. BRAVECTO Chews also kills lone star ticks for 8 weeks. BRAVECTO (fluralaner topical solution) for Dogs kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks. BRAVECTO Topical Solution for Dogs also kills lone star ticks for 8 weeks. BRAVECTO (fluralaner topical solution) for Cats kills ticks (black-legged tick and Asian longhorned tick) for 12 weeks. BRAVECTO Topical Solution for Cats also kills American dog ticks for 8 weeks.
†BRAVECTO PLUS is indicated for 2 months in cats and kittens 6 months of age and older and weighing 2.6 pounds or greater.
IMPORTANT SAFETY INFORMATION
BRAVECTO 1-MONTH (fluralaner) Chews: indicated for dogs 8 weeks of age and older. The most commonly reported adverse reactions include itching, diarrhea, vomiting, decreased appetite, elevated ALT, lethargy, and weight loss. BRAVECTO 1-MONTH is not effective against A americanum in puppies less than 6 months of age. BRAVECTO (fluralaner) Chews for Dogs: The most commonly reported adverse reactions include vomiting, lethargy, diarrhea, anorexia, and pruritus. In some cases, adverse events have been reported following use in breeding females. BRAVECTO (fluralaner topical solution) for Dogs: The most commonly reported adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. BRAVECTO (fluralaner topical solution) for Cats: The most commonly reported adverse reactions include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO Topical Solution for Cats is not effective against American dog ticks beyond 8 weeks of dosing. BRAVECTO PLUS (fluralaner and moxidectin topical solution) for Cats: The most commonly reported adverse reactions include vomiting, hair loss, itching, diarrhea, lethargy, dry skin, elevated ALT, and hypersalivation. BRAVECTO PLUS has not been shown to be effective for 2 months in kittens less than 6 months of age. Use with caution in cats that are heartworm positive. The effectiveness of BRAVECTO PLUS to prevent heartworm disease after bathing or water immersion has not been evaluated.
All BRAVECTO products contain fluralaner, which is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders.
References
- BRAVECTO® Topical Solution for Cats. Product label. Merck Animal Health; 2022.
- Freedom of Information Summary, NADA 141-459. Approved July 20, 2016.
- BRAVECTO® PLUS. Product label. Merck Animal Health; 2022.
- BRAVECTO® Chews for Dogs. Product label. Merck Animal Health; 2022.
- BRAVECTO® Topical Solution for Dogs. Product label. Merck Animal Health; 2019.
- Taenzler J, Wengenmayer C, Williams H, et al. Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs. Parasit Vectors. 2014;7:567. doi:10.1186/s13071-014-0567-6
- Wengenmayer C, Williams H, Zschiesche E, et al. The speed of kill of fluralaner (Bravecto™) against lxodes ricinus ticks on dogs. Parasit Vectors. 2014;7:525. doi:10.1186/s13071-014-0525-3
- Burgio F, Meyer L, Armstrong R. A comparative laboratory trial evaluating the immediate efficacy of fluralaner, afoxolaner, sarolaner and imidacloprid + permethrin against adult Rhipicephalus sanguineus (sensu lato) ticks attached to dogs. Parasit Vectors. 2016;9(1):626. doi:10.1186/s13071-016-1900-z
- Kynetec Heartworm and flea/tick category analysis—PetTrak™ MAT. June 2024.
- Gassel M, Wolf C, Noack S, Williams H, Ilg T. The novel isoxazoline ectoparasiticide fluralaner: selective inhibition of arthropod γ-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity. Insect Biochem Mol Biol. 2014;45:111-124. doi:10.1016/j.ibmb.2013.11.009
- Freedom of Information Summary, NADA 141-426. Approved May 25, 2014.
- Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner chewable tablets (Bravecto™), a novel systemic antiparasitic drug, in dogs after oral administration. Parasit Vectors. 2014;7:87. doi:10.1186/1756-3305-7-87
- Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration. Parasit Vectors. 2014;7:86. doi:10.1186/1756-3305-7-86